Cargando…

Erratum to: Differences in metabolic and mitogenic signalling of insulin glargine and AspB10 human insulin in rats

Detalles Bibliográficos
Autores principales:	Tennagels, N., Welte, S., Hofmann, M., Brenk, P., Schmidt, R., Werner, U.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2013
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4079385/ http://dx.doi.org/10.1007/s00125-013-3091-x

Ejemplares similares

Differences in metabolic and mitogenic signalling of insulin glargine and insulin aspart B10 in rats
por: Tennagels, N., et al.
Publicado: (2013)

Insulin Receptor Phosphorylation by Endogenous Insulin or the Insulin Analog AspB10 Promotes Mammary Tumor Growth Independent of the IGF-I Receptor
por: Gallagher, Emily Jane, et al.
Publicado: (2013)

In Vitro Metabolic and Mitogenic Signaling of Insulin Glargine and Its Metabolites
por: Sommerfeld, Mark R., et al.
Publicado: (2010)

The metabolic and mitogenic properties of basal insulin analogues
por: Tennagels, Norbert, et al.
Publicado: (2013)

Metabolic effect and receptor signalling profile of a non-metabolisable insulin glargine analogue
por: Werner, Ulrich, et al.
Publicado: (2014)

Concentrations of Insulin Glargine and Its Metabolites During Long-Term Insulin Therapy in Type 2 Diabetic Patients and Comparison of Effects of Insulin Glargine, Its Metabolites, IGF-I, and Human Insulin on Insulin and IGF-I Receptor Signaling
por: Varewijck, Aimee J., et al.
Publicado: (2013)

Mammary gland tumor promotion by chronic administration of IGF1 and the insulin analogue AspB10 in the p53(R270H/+)WAPCre mouse model
por: ter Braak, Bas, et al.
Publicado: (2015)

Erratum to: Auxiliendo, Primum Non Nocere: A Preliminary View of the DEVOTE Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Type 2 Diabetes
por: Kalra, Sanjay
Publicado: (2017)

The Role of Insulin Glargine and Human Insulin in the Regulation of Thyroid Proliferation Through Mitogenic Signaling
por: Sheng, Xiaoli, et al.
Publicado: (2019)

Equipotency of insulin glargine 300 and 100 U/mL with intravenous dosing but differential bioavailability with subcutaneous dosing in dogs
por: Werner, Ulrich, et al.
Publicado: (2020)

Erratum to: Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA
por: Hunt, Barnaby, et al.
Publicado: (2017)

ASPB welcomes Oxford University Press
por: Blatt, Michael R, et al.
Publicado: (2020)

Erratum to “Inositols in the Treatment of Insulin-Mediated Diseases”
por: Muscogiuri, Giovanna, et al.
Publicado: (2016)

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml
por: Steinstraesser, A, et al.
Publicado: (2014)

Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function
por: Hartmann, Thorsten, et al.
Publicado: (2016)

Insulin glargine overdose
por: Doğan, Fatma Sarı, et al.
Publicado: (2012)

Erratum to: The Economic Burden of Insulin-Related Hypoglycemia in Spain
por: Parekh, Witesh, et al.
Publicado: (2017)

Effect of Insulin Analogues on Insulin/IGF1 Hybrid Receptors: Increased Activation by Glargine but Not by Its Metabolites M1 and M2
por: Pierre-Eugene, Cécile, et al.
Publicado: (2012)

Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus
por: Linnebjerg, Helle, et al.
Publicado: (2016)

Erratum to: The gut microbiota profile is associated with insulin action in humans
por: Serino, Matteo, et al.
Publicado: (2012)

Insulin glargine and the risk of cancer
por: Ahmed, FA
Publicado: (2010)

Erratum: Table Correction. AMPK and Exercise: Glucose Uptake and Insulin Sensitivity
por: O'Neill, Hayley M.
Publicado: (2013)

Erratum to “Is p53 Involved in Tissue-Specific Insulin Resistance Formation?”
por: Strycharz, Justyna, et al.
Publicado: (2017)

Erratum to: Clinical and molecular genetics of neonatal diabetes due to mutations in the insulin gene
por: Støy, Julie, et al.
Publicado: (2011)

Erratum: Inhaled insulin: A “puff” than a “shot” before meals
Publicado: (2015)

Erratum. Engineering Glucose Responsiveness Into Insulin. Diabetes 2018;67:299–308
por: Kaarsholm, Niels C., et al.
Publicado: (2018)

Erratum: Methylglyoxal and insulin resistance in berberine-treated type 2 diabetic patients
Publicado: (2019)

Erratum for “Ultra‐long‐acting recombinant insulin for the treatment of diabetes mellitus in dogs”
Publicado: (2023)

A case of hypersensitivity to soluble and isophane insulins but not to insulin glargine
por: Belhekar, Mahesh N., et al.
Publicado: (2015)

Erratum to: Starting Insulin in Type 2 Diabetes: Real-World Outcomes After the First 12 Months of Insulin Therapy in a New Zealand Cohort
por: Sehgal, Shekhar, et al.
Publicado: (2015)

Erratum to: Insulin improves memory and reduces chronic neuroinflammation in the hippocampus of young but not aged brains
por: Adzovic, Linda, et al.
Publicado: (2015)

Erratum to: Heregulin-1ß and HER3 in hepatocellular carcinoma: status and regulation by insulin
por: Buta, Corina, et al.
Publicado: (2016)

Insulin autoimmune syndrome in a pregnant female: A rare case report: Erratum
Publicado: (2018)

Erratum to: Simvastatin Rapidly and Reversibly Inhibits Insulin Secretion in Intact Single-Islet Cultures
por: Scattolini, Valentina, et al.
Publicado: (2016)

Alström syndrome: A novel mutation in Saudi girl with insulin-resistant diabetes: Erratum
Publicado: (2017)

Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes
por: Tarigan, Tri Juli Edi, et al.
Publicado: (2021)

Hepatic Insulin Resistance Model in the Male Wistar Rat Using Exogenous Insulin Glargine Administration
por: Sarmiento-Ortega, Victor Enrique, et al.
Publicado: (2023)

Erratum: Delayed Response to U-500 Regular Insulin. Clinical Diabetes 2018;36: 77–79 (DOI: 10.2337/cd16-0058)
por: Davidson, Mayer B.
Publicado: (2018)

Evaluation of the innate immunostimulatory potential of originator and non-originator copies of insulin glargine in an in vitro human immune model
por: Luna, Ernesto, et al.
Publicado: (2018)

Erratum: Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study
por: Hodson, L, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ce87bj4qt3pts3c0m5jk113ec8